- Study met its primary endpoint with 80.1% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59.2% of patients treated with vehicle (P
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
On 6ix: 6ix.com/news/arcutis-announces-positive-topline-results-from-stratum-pivotal-phase-3-trial-of
Watch Arcutis Biotherapeutics' latest callArcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings Call · Replay · Aug 5Read the transcript of Arcutis Biotherapeutics (NASDAQ:ARQT) Q2 2026 Earnings CallArcutis Biotherapeutics' next earnings callArcutis Biotherapeutics (NASDAQ:ARQT) Q3 2026 Earnings Call · Nov 4, 2026 at 4:30 PM ESTRegister
Arcutis Biotherapeutics, Inc. on 6ix
In the deck
Story so far
- CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
- Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
- Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Earlier from Arcutis Biotherapeutics
- CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care
- Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
- Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis
- Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Later from Arcutis Biotherapeutics
- Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis
- FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
- Arcutis to Host Investor Conference Call Today to Discuss the FDA Approval of ZORYVE™ (roflumilast) Cream 0.3% for Plaque Psoriasis
- Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock
- Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock
Follow Arcutis Biotherapeutics into a list and get an email when it puts out news.
Follow Arcutis Biotherapeutics